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Mid-Gastrointestinal Bleeding
Monjur Ahmed
Abstract
Mid-gastrointestinal bleeding constitutes a small proportion of all cases of gas-
trointestinal bleeding. It is more difficult to manage mid-gastrointestinal bleeding 
than upper or lower gastrointestinal bleeding. The etiology differs in younger and 
older age groups. The clinical presentation, investigations, and management are also 
different. Capsule endoscopy has improved the diagnostic accuracy to a great extent. 
Device-assisted enteroscopies (balloon-assisted enteroscopies and spiral enteros-
copy) have both diagnostic and therapeutic potentials. Most of the time, patients 
present with obscure gastrointestinal bleeding which could be overt or occult. 
Another common presentation is iron deficiency anemia. A stepwise approach is 
essential to accurately diagnose and manage mid-gastrointestinal bleeding.
Keywords: small bowel bleed, occult gastrointestinal bleed, obscure gastrointestinal 
bleed, capsule endoscopy and gastrointestinal bleed, small bowel angioectasia
1. Introduction
Most of the gastrointestinal (GI) bleeding occurs from the upper and lower 
gastrointestinal tract. Mid-gastrointestinal (GI) bleeding refers to small bowel bleed 
anywhere from the ampulla of Vater to the ileocecal valve [1]. It occurs in 5–10% 
of all cases of gastrointestinal bleeding [2]. It is the most common cause of obscure 
GI bleeding, i.e., when the source of bleeding cannot be identified anywhere in the 
gastrointestinal tract [3, 4]. Management of mid-GI bleeding can be challenging 
to a gastroenterologist although various diagnostic and therapeutic tools are now 
available to evaluate and treat mid-GI bleeding. Despite the availability of various 
endoscopies and imaging studies, the exact cause of mid-GI bleeding can be still 
elusive in about one third of cases [5]. The etiology, clinical presentation, evaluation, 
investigations, and management of mid-GI bleeding will be discussed in this chapter.
2. Etiology
There are various etiologies of mid-GI bleeding, but their frequency depends 
on patient’s age and underlying comorbidities [6]. Below the age of 40, the most 
common causes include Crohn’s disease, Dieulafoy’s lesion, small bowel tumors, 
Meckel’s diverticulum, and polyposis syndrome. Small bowel tumors could be 
benign or malignant [7]. Benign ones include small gastrointestinal stromal tumors 
(GIST), benign neuroendocrine tumors (particularly small carcinoid), heman-
gioma, adenoma, leiomyoma, lipoma, and neurofibroma. Malignant ones include 
large GIST, adenocarcinoma, lymphoma, malignant neuroendocrine tumors, 
leiomyosarcoma, and metastatic tumor from melanoma, lung, or breast [8–11]. 
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Rarely, polyposis syndromes involving the small bowel may present with mid-GI 
bleeding. These include familial adenomatous polyposis, Peutz-Jeghers syndrome, 
and generalized juvenile polyposis. Over the age of 40, the most common causes 
of mid-GI bleeding include angioectasia, nonsteroidal anti-inflammatory drug 
(NSAID)-induced ulcers, Dieulafoy’s lesion, and small bowel tumors. On rare occa-
sions, other small bowel lesions can cause gastrointestinal bleeding. These include 
small intestinal diverticuli, small intestinal varices, hereditary hemorrhagic telangi-
ectasia, Kaposi sarcoma, intestinal tuberculosis, blue rubber bleb nevus syndrome, 
hematobilia, hemosuccus entericus, aortoenteric fistula, infectious enteritis, 
radiation enteritis, ulcerative jejunoileitis due to celiac disease, cryptogenic multifo-
cal ulcerous stenosing enteritis [12], amyloidosis, Behcet’s disease, pseudoxanthoma 
elasticum, and Ehlers-Danlos syndrome [13]. The incidence of small bowel neu-
roendocrine tumors (SBNET) has been increasing over the last few decades, and 
they are now considered as the most common primary malignancy of small bowel. 
Adenocarcinomas are generally seen in the proximal small bowel, whereas SBNET 
and lymphoma are commonly located in the distal small bowel. Sarcomas (GIST 
and non-GIST mesenchymal tumors: leiomyosarcoma, liposarcoma, fibrosarcoma, 
Kaposi’s sarcoma, angiosarcoma) are evenly located throughout the small bowel.
3. Clinical presentation
Patients with mid-GI bleeding generally present with melena, occult gastro-
intestinal bleeding (anemia with heme-positive stool), or iron deficiency anemia. 
Sometimes, they may present with hematochezia as well when there is brisk mid-gut 
bleeding. Hematemesis is rare but can happen if bleeding occurs proximal to the liga-
ment of Treitz. Patients can have abdominal pain, constipation, diarrhea, or consti-
tutional symptoms like fever, anorexia, or weight loss depending on the underlying 
etiology. Symptoms (fatigue, shortness of breath, dysphagia due to esophageal web) 
and signs (pallor of conjunctiva, atrophic glossitis, and koilonychia) can be present 
depending on the severity and chronicity of iron deficiency anemia [14]. Patients may 
give history of receiving multiple blood transfusions acutely, subacutely, or chroni-
cally despite having multiple endoscopies, colonoscopies, and imaging studies.
4. Clinical evaluation
A thorough history and physical examination are essential in the evaluation 
of mid-GI bleeding. Besides the symptoms and signs mentioned above, there are 
certain clinical clues which may direct us to suspect the underlying etiology of 
mid-GI bleeding:
• Drug history: NSAIDs.
• Personal history: aortic stenosis (suspecting Heyde syndrome), cancer, mela-
noma, lymphoma, immunosuppressive state including human immunodefi-
ciency virus (HIV) infection, celiac disease, radiation, polyposis syndrome.
• Family history: early colorectal cancer or endometrial cancer (suspecting 
Lynch syndrome).
• Hyperpigmentation around the mouth and on the lips, fingers, or toes may 
suggest Peutz-Jeghers syndrome.
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• Telangiectasia on the lips and tongue may suggest hereditary hemorrhagic 
telangiectasia.
• Itchy blistering rash on the extensor aspect of the elbows, knees, buttocks, 
back, and scalp may suggest dermatitis herpetiformis.
• Cutaneous Kaposi’s sarcoma.
• Oral aphthous ulcers, genital ulcers, and uveitis may suggest Behcet’s syndrome.
• Cutaneous manifestations of pseudoxanthoma elasticum and Ehlers-Danlos 
syndrome.
5. Investigations
The various investigations used for management of mid-GI bleeding include 
wireless video capsule endoscopy (VCE), push enteroscopy, device-assisted enter-
oscopy (DAE), multiphasic CT enterography (CTE), magnetic resonance enterog-
raphy (MRE), bleeding scan, Meckel’s scan, angiography, and rarely laparoscopy 
with intraoperative enteroscopy [15–18].
5.1 VCE
VCE has revolutionized the visualization of the entire mucosa of the small 
bowel. It was approved by the US Food and Drug Administration (FDA) in 2001. 
The video capsule (size: 13 × 27.9 mm) takes 2 pictures per second with a total of 
approximately 57,600 color pictures wirelessly over a period of 8 hours [19]. It can 
detect subtle mucosal changes which cannot be detected by imaging studies. VCE 
is very useful not only in patients with chronic or intermittent mid-GI bleeding but 
also in acute overt mid-GI bleeding. VCE should be done as soon as possible after 
the bleeding episode ideally within 14 days in the case of chronic or recurrent overt 
mid-GI bleeding and within 24–72 hours of acute overt mid-GI bleeding for maxi-
mal diagnostic yield [20]. The European Society of Gastrointestinal Endoscopy 
(ESGE) recommends that patients should take 2 L of polyethylene glycol (PEG) 
and simethicone (80–200 mg) prior to VCE. Prokinetic drugs (metoclopramide 
or domperidone) should be given if the video capsule stays in the stomach for 
more than 30–60 minutes as shown by real-time VCE viewer [21, 22]. Ideally video 
capsule should be placed endoscopically into the small bowel by using a capsule 
endoscope delivery device in patients with dysphagia or abnormal gastrointestinal 
anatomy or delayed gastric emptying where there will be increased risk of incom-
plete VCE study [23]. It is safe to perform VCE in patients with cardiac pacemaker, 
automatic implantable cardioverter-defibrillator (AICD), and left ventricular assist 
device [24].
5.2 Push enteroscopy
Push enteroscopy is a very useful tool in the evaluation of lesion seen in the 
proximal part of the small bowel by VCE. Push enteroscopy is generally done by a 
dedicated push enteroscope (250 cm long) or a pediatric or standard colonoscope. 
Gastric looping and duodenal angulation prevent advancement of the scope. 
An overtube back-loaded on to the scope or a stiffening wire through the biopsy 
channel of the scope helps prevent loop formation of the scope allowing deeper 
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intubation of the small bowel. The actual depth of insertion of small bowel by push 
enteroscopy is difficult to measure but varies (120–180 cm beyond the ligament of 
Treitz) among endoscopists and patients [25]. Push enteroscopy has both diagnos-
tic and therapeutic potential including biopsy, hemostasis, and tattooing [26].
5.3 DAE
DAE includes balloon-assisted enteroscopy (single balloon and double balloon) 
and spiral enteroscopy.
Single-balloon enteroscopy (SBE) and double-balloon enteroscopy (DBE) 
were developed in 2006 and 2001, respectively, to examine the entire small bowel 
mucosa. Both procedures are bidirectional, i.e., the enteroscope is introduced 
anterogradely through the mouth and retrogradely through the anus, and the 
midway point is marked by tattooing or endoclipping [27]. Although the rate of 
complete visualization of the small bowel is three times (66 vs. 22%) higher with 
DBE than that with SBE [28], the diagnostic and therapeutic yields of these two 
procedures do not differ significantly [29]. In spiral enteroscopy (SE), the small 
bowel is pleated on the enteroscope by a screw operated by a machine, and the 
rotational force is converted into a linear force. In one study, complete enteroscopy 
was successful in 92% of cases of bidirectional DBE and 8% of cases of SE, although 
the diagnostic and therapeutic outcomes were not statistically different [30].
5.4 CTE
CTE is a useful tool in the evaluation of mid-GI bleed due to vascular lesion. 
Characteristic enhancement of the vascular lesion can be seen [31]. They are 
classified as angioectasia, arterial lesions (Dieulafoy’s lesion and arteriovenous 
malformation), and venous lesions (vascular lesion with unusual morphology). 
Active bleeding is evidenced by progressive accumulation of contrast material over 
the three phases on the dependent surface of the intestine or distributed over a wide 
area by peristalsis. CT enterography is also useful in the detection of inflammatory 
and neoplastic condition of the small bowel [32].
5.5 MRE
MRE is a noninvasive radiation-free method of evaluating the entire small bowel. 
It can detect the mural thickening (>4 mm) and mass lesion of the small bowel. These 
lesions could be secondary to inflammatory and benign conditions (like Crohn’s disease, 
adenoma, lipoma, fibroepithelial polyps) or malignant conditions (like neuroendocrine 
tumors, GIST, adenocarcinoma, lymphoma, and Peutz-Jeghers syndrome) [33, 34].
5.6 Bleeding scan
Bleeding scan is a nuclear medicine test performed by injecting 99 m techne-
tium-labeled red blood cells (RBC). It can detect extravasation of tagged RBC if the 
bleeding rate is 0.1 ml/minute or more. It is a highly sensitive test in detecting active 
bleeding in the gastrointestinal tract and can localize the site of bleeding accurately 
in 52% of cases [35].
5.7 Meckel’s scan
Meckel’s scan is also a nuclear medicine test performed by injecting 99 m 
technetium pertechnetate which has affinity for the gastric mucosa. It is positive in 
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patients with Meckel’s diverticulum with heterotopic/ectopic gastric mucosa. Acid 
secretion from the gastric mucosa can cause ulceration and bleeding near or adja-
cent to the diverticulum. In children, Meckel’s scan is performed early, whereas in 
adults, it is generally performed late in the evaluation of mid-GI bleeding.
5.8 CT angiography (CTA)
CTA is increasingly being done in patients with less brisk mid-GI bleeding. 
CTA can detect the bleeding site if the bleeding rate is 0.3 ml/minute or more [36]. 
However, CTA exposes the patient to ionizing radiation, and intravenous contrast 
is required. So patients with contrast allergy, renal failure, and pregnancy should 
avoid CTA.
5.9 Conventional mesenteric angiography (CMA)
CMA is rarely done in the evaluation of mid-GI bleeding unless there is ongoing 
significant bleeding and patient had hemodynamic instability, positive CTE, or 
bleeding scan; and embolization is considered to stop the bleeding. However, there 
is risk of bowel wall infarction following embolization therapy. CMA can also detect 
small bowel varices in patients with portal hypertension and Meckel’s diverticulum 
by the finding of an anomalous long branch of superior mesenteric artery traversing 
the mesentery toward the right lower quadrant and supplying the diverticulum.
5.10 Gallium-68 dotatate PET/CT scan
Gallium-68 dotatate PET/CT scan is now considered as the best scan for detect-
ing SBNET as 70–90% of them have somatostatin receptors. It has much better 
imaging quality and can detect more lesions than Octreoscan [37]. But it does not 
replace CTE or MRE for those SBNET which are not somatostatin receptor positive.
5.11 Intraoperative enteroscopy
Intraoperative enteroscopy is done in the operating room when other modali-
ties of investigations fail to detect the source of bleeding. The scope is introduced 
through the mouth or through an enterotomy, and whole small bowel can be evalu-
ated. It is diagnostic as well as therapeutic in achieving hemostasis in about 70% of 
cases.
6. Management
A systematic approach is essential to manage mid-GI successfully. Mid-GI 
bleeding is generally established when no source of potential bleeding is found in 
the upper or lower gastrointestinal tract after doing bidirectional endoscopy, i.e., 
upper endoscopy (including examination with a side-viewing duodenoscope) and 
ileocolonoscopy. Second-look bidirectional endoscopy should be done considering 
substantial initial endoscopic miss rates [38]. Next step to evaluate is whether the 
patient is hemodynamically stable or unstable and whether the patient is having 
occult or overt GI bleeding. The first investigation to evaluate mid-GI bleeding in 
a hemodynamically stable patient is VCE unless there are contraindications like 
small bowel obstruction [39]. On the other hand, in a hemodynamically unstable 
patient, the first investigation will be angiography for both diagnostic and thera-
peutic purposes [40].
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Depending on the location of bleeding lesion in VCE, push enteroscopy or DAE 
should be done, i.e., push enteroscopy for lesion in the proximal part of the small 
bowel and DAE for lesion in the mid or distal part of the small bowel. If the VCE is 
negative, the next step will depend on whether the patient has ongoing blood loss, 
the rate of blood loss, and the presence of comorbidities:
a. If the patient has ongoing blood loss without significant comorbidities, DAE, 
CTE/MRE, or even laparoscopy with intraoperative enteroscopy should be 
considered to stop the bleeding.
b. If the patient does not have ongoing blood loss, further evaluation can be 
stopped.
c. If the patient has significant comorbidities and slow rate of blood loss, further 
investigation could be reasonably stopped. Patient should be observed with 
periodic monitoring of complete blood count (CBC), and iron supplementa-
tion and/or blood transfusion should be given as necessary basis.
Definitive therapy should be given according to the findings seen in the above 
investigations. Treatment modalities of some of the common conditions are listed 
below:
• Small bowel angioectasia: it is by far the commonest cause of mid-GI bleed-
ing. Endoscopic ablation is the treatment of choice. Sometimes patients may 
present with recurrent anemia due to bleeding from widespread or inacces-
sible angioectasia, and endoscopic treatment is risky because of patients’ 
comorbidities or old age. Pharmacologic treatment is generally offered in those 
cases. Thalidomide prevents angiogenesis by inhibiting vascular endothelial 
growth factor (VEGF). One study showed that thalidomide was effective in 
reducing the rate of recurrent small bowel bleeding due to vascular malforma-
tions [41]. Octreotide decreases mesenteric blood flow, inhibits angiogenesis, 
and improves platelet aggregation. One meta-analysis showed that octreotide 
therapy reduced the transfusion requirement in patients with recurrent 
bleeding from gastrointestinal vascular malformations [42]. Other treatment 
modalities for different conditions include:
• Isolated jejunal and ileal bleeding ulcers due to NSAIDs: hold NSAIDs, endoscopic 
treatment, and/or embolization. In rat model, proton pump inhibitors were found 
to worsen NSAID-induced small bowel injury by inducing dysbiosis [43].
• Dieulafoy’s lesion: endoscopic (argon plasma coagulation, hemoclip, injec-
tion therapy) or angiographic intervention (embolization) or surgery if those 
interventions fail [44].
• Small bowel varices: endoscopic treatment if within reach of endoscope. 
Angiography, transjugular intrahepatic portosystemic shunt (TIPS) place-
ment, or surgery if endoscopic hemostasis fails or is beyond the reach of 
endoscope [45].
• SBNET: surgical resection is the treatment of choice for locoregional disease. 
Long-acting somatostatin analogs are given for functional and nonfunctional 
metastatic SBNET because of their antiproliferative effects and ability to 
control carcinoid symptoms [46].
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• Adenocarcinoma of small bowel: surgery, chemotherapy, and checkpoint 
inhibitors.
• GIST: surgery and tyrosine kinase inhibitors.
• Non-GIST mesenchymal tumors: surgery.
• Benign tumors:
Adenoma: endoscopic resection.
Lipoma, leiomyoma, and hamartomas: segmental resection.
Peutz-Jeghers syndrome: segmental resection or endoscopic resection. Because 
some patients are young with widespread polyps, endoscopic treatment should be 
preferred [47].
• Metastatic tumor to the small bowel: palliative treatment.
• Meckel’s diverticulum: surgery.
• Crohn’s disease: endoscopic treatment, embolization, corticosteroid,  
5-aminosalicylic acid, 6-mercaptopurine/azathioprine, infliximab, and  
surgery [48].
• Ulcerative jejunoileitis due to celiac disease: surgical resection of the ulcerated 
segment, corticosteroid, elimination diet, and total parenteral nutrition.
7. Prognosis
Prognosis depends on the etiology of the lesion causing mid-GI bleeding. 
Vascular lesions carry a good prognosis if they can be successfully treated endo-
scopically, radiologically, or surgically. Most of the time, vascular lesions can be 
managed endoscopically. Surgical intervention is required if the bleeding cannot 
be managed endoscopically or by interventional radiology. Surgery is also required 
for benign and malignant small bowel tumors, ulcerative jejunoileitis due to celiac 
disease, and refractory bleeding Crohn’s ulcers. Sometimes, patients’ comorbidities 
or old age do not allow invasive procedures or surgery. Symptomatic and palliative 
treatments are offered in those cases. Sometimes, mid-GI bleeding remains obscure. 
Patients end up getting multiple hospitalizations, multiple diagnostic tests, and 
multiple blood transfusions.
8. Conclusion
Mid-GI bleeding is common in our day-to-day clinical practice. Capsule endos-
copy and imaging studies have made the diagnostic evaluations much easier than 
before. Balloon-assisted enteroscopy and spiral enteroscopy are generally done 
for therapeutic interventions. Interventional radiology and surgery are required if 
there is massive bleeding or endoscopic therapeutic interventions fail. After hemo-
stasis is obtained, treatment of the underlying condition should be done. Patient’s 
age, comorbidities, pros and cons of the procedures, and radiological and surgical 
interventions should be considered.
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